使用ASDAS评估起始首个生物制剂治疗的轴性脊柱关节炎患者的疾病活动度与治疗反应:是否遵循ASAS推荐
基于葡萄牙Reuma.pt注册的666例起始首个bDMARD的轴性脊柱关节炎患者,81%有基线ASDAS,74%在3个月和/或6个月有ASDAS。336例完整评估者中58%在3个月、60%在6个月满足ASAS继续治疗标准,3至6个月间86%维持应答。
要点
- 666例中81%有基线ASDAS,74%在3个月和/或6个月有ASDAS。
- 336例完整评估者中58%在3个月、60%在6个月满足ASAS继续治疗标准。
- 3至6个月间86%维持应答,3个月无应答者中25%在6个月出现应答。
核心结论
- 葡萄牙风湿科医生对起始bDMARD的axSpA患者广泛评估ASDAS,多数患者在3个月内应答,但等待至6个月再决定是否继续治疗是合理的。
研究设计与样本
- 基于葡萄牙Reuma.pt注册的队列研究,纳入起始首个bDMARD并完成基线、3个月和6个月访视的axSpA患者,共666例。
主要发现
- 666例中540例(81%)有基线ASDAS,493例(74%)在3个月和/或6个月也有ASDAS。
- ASDAS缺失时没有哪一种替代结局指标被主要使用。
- 336例完整ASDAS评估者中,58%在3个月、60%在6个月满足ASAS继续治疗标准,3至6个月间86%维持应答。
- 147例3个月无应答者中25%在6个月出现应答。
- 两个时间点均应答者更多为男性(65% vs 45%)且更年轻(平均年龄35 vs 38岁)。
关键数值与推荐
- 治疗应答定义为∆ASDAS ≥1.1,在3个月和6个月按无应答、仅3个月应答、仅6个月应答、两个时间点均应答四种模式分析。
- ASAS继续治疗标准在3个月时58%、6个月时60%的336例完整评估者中被满足。
临床怎么用
- 原文结论认为多数患者在3个月内应答,但等待至6个月再决定是否继续治疗是合理的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the proportion of patients with axial spondyloarthritis (axSpA) who had ASDAS calculated at baseline and at least once within two follow-up visits after starting their first bDMARD; and to evaluate the likelihood of meeting ASAS criteria for treatment continuation at 3 and 6 months. METHODS: Patients with axSpA from the Reuma.pt registry who initiated their first bDMARD and attended baseline, 3-month (3 M), and 6-month (6 M) visits were included. Availability of ASDAS at baseline was cross-tabulated with its availability in ≥1 follow-up visit. When ASDAS was absent, the use of alternative outcome measures was evaluated. Treatment response (∆ASDAS ≥1.1) at 3 M and 6 M was analyzed across four response patterns: no response, 3 M only, 6 M only, or both. RESULTS: A total of 666 patients were included. Most had ASDAS at baseline (N = 540; 81 %), and 493 (74 %) also had ASDAS at 3 M and/or 6 M. No alternative outcome measure was predominantly used when ASDAS was absent. Among 336 patients with complete ASDAS evaluation, 58 % met ASAS continuation criteria at 3 M and 60 % at 6 M, with 86 % of response maintenance between 3 M and 6 M. Additionally, 25 % of 147 non-responders at 3 M responded at 6 M. Responders at both timepoints were more often male (65 % vs 45 %) and younger (mean age 35 vs 38 years). CONCLUSION: ASDAS is widely assessed in axSpA patients starting bDMARDs by Portuguese rheumatologists. Most patients respond within 3 months but waiting until 6 months to determine treatment continuation is reasonable.
引用
- Santos ME, Ramiro S, van der Heijde D, et al. The use of ASDAS to evaluate disease activity and response to treatment in patients with axial spondyloarthritis starting the first biological drug: Are ASAS recommendations being followed? Semin Arthritis Rheum. 2025. PMID: 40712275. doi:10.1016/j.semarthrit.2025.152781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。